https://orcid.org/0000-0002-8297-556X
-
Views
-
Cite
Cite
Taryn Youngstein, Patrycja Hoffmann, Ahmet Gül, Thirusha Lane, Rene Williams, Dorota M. Rowczenio, Huri Ozdogan, Serdal Ugurlu, John Ryan, Len Harty, Sean Riminton, Alex P. Headley, Joachim Roesler, Norbert Blank, Jasmin B. Kuemmerle-Deschner, Anna Simon, Adrian S. Woolf, Philip N. Hawkins, Helen J. Lachmann, International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors, Rheumatology, Volume 56, Issue 12, December 2017, Pages 2102–2108, https://doi.org/10.1093/rheumatology/kex305
Close - Share Icon Share
Abstract
To provide outcome data concerning pregnancies exposed to the Interleukin-1 (IL-1) inhibitors prior to conception in both men and women, during pregnancy and breast feeding.
Retrospective data were collected from members of the International Society for Systemic Autoinflammatory diseases and collated in a single centre. A uniform data collection sheet was used to obtain standardized data including maternal age and diagnosis, type, duration of and response to IL-1 blockade, pregnancy duration, delivery, mode of feeding and neonatal development.
There were 31 maternal-exposed pregnancies from seven countries and we report the first data on paternal exposure: six to anakinra and five to canakinumab, with no negative outcomes. We also report the first data on canakinumab-exposed pregnancies: eight pregnancies that resulted in the delivery of seven healthy infants of normal gestational age and birthweight. There were 23 anakinra-exposed pregnancies resulting in the birth of 21 healthy infants, and one baby with unilateral renal agenesis and ectopic neurohypophysis. There were two first trimester miscarriages affecting a mother with active disease. There were no serious neonatal infections. Fourteen infants were breast fed with no complications. There were no reports of developmental delay, with follow-up of up to 10 years (median 18 months).
This series substantially increases the published experience of IL-1 blockade and reproduction including the first data on canakinumab and on paternal exposure to these agents. Data are generally reassuring, although the case of renal agenesis is the second reported in an anakinra-exposed pregnancy.
- pregnancy
- interleukin-1
- abortion, spontaneous
- birth weight
- breast feeding
- follow-up
- gestational age
- infant
- maternal age
- mothers
- paternal exposure
- pituitary gland, posterior
- pregnancy outcome
- pregnancy trimester, first
- reproductive physiological process
- diagnosis
- renal agenesis
- anakinra
- conception
- unilateral agenesis of kidney
- neonatal infections
- developmental delay
- neonatal development
- duration of gestation
- autoinflammatory disease
- canakinumab
Comments